Three more days of nationwide mail access for mifepristone were preserved after the Supreme Court extended its stay of a lower-court order until Thursday.
The pause blocks a 5th Circuit ruling that would have forced patients nationwide to obtain the abortion pill in person at clinics and barred mail delivery or pharmacy dispensing after telemedicine.
Louisiana triggered the dispute by suing the FDA, arguing against remote-access rules for a drug used in most US abortions.
Danco Laboratories and GenBioPro sought the temporary relief while preparing an emergency appeal, keeping a major post-Roe abortion access fight before the high court.
If courts can overrule the FDA on one drug, what common medications could be challenged next?
With public trust in health agencies waning, how will future drug approvals be decided?
Supreme Court Decision Looms: The Future of Mifepristone Access and FDA Authority in the U.S.
Overview
On May 14, 2026, the Supreme Court faces a pivotal decision as Justice Alito’s temporary stay on new restrictions for mifepristone expires. This follows Louisiana’s challenge to FDA rules, arguing they undermine the state’s abortion ban. The 5th Circuit sided with Louisiana, seeking to ban mailing mifepristone and require in-person doctor visits. Manufacturers appealed, warning these changes would cut off nationwide access. Now, the Supreme Court must decide whether to let the restrictions take effect or maintain current access, a choice with major consequences for patients, healthcare providers, and the future of federal drug regulation.